QNRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.9M
-10.1%
5.5M
+6.7%
5.1M
+13.5%
4.5M
+12.5%
4.0M
R&D
2.7M
-26.8%
3.6M
+5.6%
3.4M
+10.9%
3.1M
+35.8%
2.3M
SG&A
2.3M
+22.8%
1.8M
+8.8%
1.7M
+19.2%
1.4M
-18.1%
1.7M
Operating Income
-4923012
+10.1%
-5473574
-6.7%
-5131210
-13.5%
-4520435
-12.5%
-4019925
EBITDA
-4898012
+10.1%
-5448574
-6.7%
-5106210
-13.6%
-4495435
-12.5%
-3994925
Net Income
-4870759
+9.3%
-5371042
-7.5%
-4997735
-14.9%
-4348373
-10.1%
-3948165
EPS (Basic)
$-0.97
+48.9%
$-1.90
-7.3%
$-1.77
-2.3%
$-1.73
+74.2%
$-6.71
EPS (Diluted)
$-0.97
+48.9%
$-1.90
-7.3%
$-1.77
-2.3%
$-1.73
+74.2%
$-6.71
Shares (Diluted)
5.0M
+78.0%
2.8M
+0.1%
2.8M
+12.8%
2.5M
+326.7%
588.2K
Quoin Pharmaceuticals, Ltd. American (QNRX) — Financials